← back to search

David Jones

Newcastle upon Tyne Hospital · US
🔎 Find collaborators in Hepatology · Epidemiology →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Hepatology · Epidemiology
Research interest
Research interests include Liver Diseases and Immunity, Liver Disease Diagnosis and Treatment, Pediatric Hepatobiliary Diseases and Treatments, and Drug Transport and Resistance Mechanisms.
h-index
58
citations
13,341
works
281
NIH funding
primary concept
Medicine
email

Recent publications

Network meta-analysis: relative clinical efficacy and safety of elafibranor versus seladelpar as second-line treatment for patients with primary biliary cholangitis.
2026cited by 0position: contributordoi
Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acid.
2026cited by 0position: contributordoi
Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results
The American Journal of Gastroenterology 2025cited by 8position: middledoi
Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?
2024cited by 25position: contributordoi
Relationship between pruritus and sleep in participants with primary biliary cholangitis in the Phase 2b GLIMMER trial
Journal of Patient-Reported Outcomes 2024cited by 14position: lastdoi
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis
New England Journal of Medicine 2023cited by 245position: middledoi
Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
Hepatology 2023cited by 74position: middledoi
Setanaxib, a first‐in‐class selective NADPH oxidase 1/4 inhibitor for primary biliary cholangitis: A randomized, placebo‐controlled, phase 2 trial
Liver International 2023cited by 64position: middledoi
Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis
Hepatology 2023cited by 43position: middledoi
Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis
Alimentary Pharmacology & Therapeutics 2023cited by 34position: middledoi
Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial
Hepatology Communications 2023cited by 33position: firstdoi
Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial.
2023cited by 24position: contributordoi
Critical shortfalls in the management of PBC: Results of a UK-wide, population-based evaluation of care delivery
JHEP Reports 2023cited by 24position: middledoi
Regulation of immune responses in primary biliary cholangitis: a transcriptomic analysis of peripheral immune cells.
2023cited by 6position: contributordoi
Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls
Gastroenterology 2022cited by 95position: middledoi
GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With Pruritus
Clinical Gastroenterology and Hepatology 2022cited by 90position: middledoi
Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis
JHEP Reports 2022cited by 47position: lastdoi
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs
Journal of Hepatology 2021cited by 180position: middledoi
A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA
Journal of Hepatology 2021cited by 175position: middledoi
Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis
Liver International 2021cited by 88position: middledoi
TGF-β2 silencing to target biliary-derived liver diseases
Gut 2020cited by 43position: middledoi
Effects of Primary Biliary Cholangitis on Quality of Life and Health Care Costs in the United Kingdom
Clinical Gastroenterology and Hepatology 2020cited by 24position: lastdoi
British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis
Gut 2019cited by 281position: middledoi
The challenges of primary biliary cholangitis: What is new and what needs to be done
Journal of Autoimmunity 2019cited by 115position: middledoi
A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis
Hepatology Communications 2019cited by 95position: middledoi
Fatigue in chronic liver disease: New insights and therapeutic approaches.
2019cited by 68position: contributordoi
PBC‐10: a short quality of life measure for clinical screening in primary biliary cholangitis
Alimentary Pharmacology & Therapeutics 2019cited by 21position: lastdoi
Editorial: rapid assessment of health‐related quality of life in primary biliary cholangitis—no excuse not to ask. Authors' reply
Alimentary Pharmacology & Therapeutics 2019cited by 0position: lastdoi
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score
˜The œLancet. Gastroenterology & hepatology 2018cited by 162position: middledoi
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study
˜The œLancet. Gastroenterology & hepatology 2017cited by 185position: firstdoi

Grants

Collaborative Research: The Connection between Astrophysical Transients and their Host Galaxies Across Cosmic Time
NSF2510993$521,0802025–2028PIRePORTER
EPSCoR Research Fellows: NSF: Building a Duke University and University of Hawaii Collaboration for the Next Decade of Supernova Cosmology
NSF2429450$277,6082025–2026PIRePORTER
Cosmology in the Local Volume with Hawai'i Supernova Flows
NSF2407632$788,0712024–2027PIRePORTER
Statewide effort to diversify undergraduate engineering student population.
NSF1848696$199,9992018–2022PIRePORTER
Strengthening Transitions into Engineering Programs
NSF0622274$1,836,0552006–2012PIRePORTER
Connection to PREPnet/NSFNET for Gwynedd-Mercy College
NSF9406978$23,5001994–1996PIRePORTER
Segmental Integration of Spinal Cord Descending 5HT and NE Neuron Function
NSF8820008$268,2001989–1992PIRePORTER
Comprehensive Assistance to Undergraduate Science Education
NSF7807060$131,4001978–1982PIRePORTER

Frequent collaborators

Gideon M. Hirschfield · University Health Network12 papers (2015–2025)Cynthia Levy · University of Miami12 papers (2015–2025)Marlyn J. Mayo · Center for Digestive and Liver Diseases8 papers (2015–2025)Christopher L. Bowlus · Washington State University6 papers (2019–2025)John M. Vierling · Baylor College of Medicine5 papers (2015–2025)George Mells · Cambridge University Hospitals NHS Foundation Trust5 papers (2019–2023)Andreas E. Kremer · University of Zurich5 papers (2021–2025)Marco Carbone · Istituti di Ricovero e Cura a Carattere Scientifico4 papers (2020–2023)Charles A. McWherter · CymaBay Therapeutics (United States)4 papers (2021–2025)Pietro Invernizzi · University Health Network4 papers (2015–2023)Steven Flack · University of Cambridge4 papers (2019–2023) · 3 papers (2023–2026)Douglas Thorburn · University College London3 papers (2019–2023)Laith Alrubaiy · University of London3 papers (2019–2023) · 3 papers (2015–2022)Palak Trivedi · University of Amsterdam3 papers (2023–2025)Keith D. Lindor · Mayo Clinic3 papers (2015–2015)Albert Parés · Universitat Autònoma de Barcelona3 papers (2015–2021)Mark G. Swain · Newcastle University3 papers (2023–2023)Kris V. Kowdley · Velocity Clinical Research (United States)3 papers (2021–2025)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Hepatology · Epidemiology →